Evidence map›Paper›PMID 24850736›Full record

ArticleJournal of virology2014

A single amino acid in EBNA-2 determines superior B lymphoblastoid cell line growth maintenance by Epstein-Barr virus type 1 EBNA-2.

Stelios Tzellos, Paulo B Correia, Claudio Elgueta Karstegl, Laila Cancian, Julian Cano-Flanagan, Michael J McClellan, Michelle J West, Paul J Farrell

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 52 citations in OpenAlex.

  1. Efficacy of Immune Checkpoint Inhibitors and Oncoviruses in Solid Tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Stelios TzellosSection of Virology, Imperial College Department of Medicine, St. Mary's Hospital Campus, London, United Kingdom.
Paulo B CorreiaSection of Virology, Imperial College Department of Medicine, St. Mary's Hospital Campus, London, United Kingdom.
Claudio Elgueta KarsteglSection of Virology, Imperial College Department of Medicine, St. Mary's Hospital Campus, London, United Kingdom.
Laila CancianSection of Virology, Imperial College Department of Medicine, St. Mary's Hospital Campus, London, United Kingdom.
Julian Cano-FlanaganSchool of Life Sciences, University of Sussex, Falmer, Brighton, United Kingdom.
Michael J McClellanSchool of Life Sciences, University of Sussex, Falmer, Brighton, United Kingdom.
Michelle J WestSchool of Life Sciences, University of Sussex, Falmer, Brighton, United Kingdom.
Paul J FarrellSection of Virology, Imperial College Department of Medicine, St. Mary's Hospital Campus, London, United Kingdom p.farrell@imperial.ac.uk.
St Mary's Hospital · GBUniversity of Sussex · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledSequence differences in the EBNA-2 protein mediate the superior ability of type 1 Epstein-Barr virus (EBV) to transform human B cells into lymphoblastoid cell lines compared to that of type 2 EBV. Here we show that changing a single amino acid (S442D) from serine in type 2 EBNA-2 to the aspartate found in type 1 EBNA-2 confers a type 1 growth phenotype in a lymphoblastoid cell line growth maintenance assay. This amino acid lies in the transactivation domain of EBNA-2, and the S442D change increases activity in a transactivation domain assay. The superior growth properties of type 1 EBNA-2 correlate with the greater induction of EBV LMP-1 and about 10 cell genes, including CXCR7. In chromatin immunoprecipitation assays, type 1 EBNA-2 is shown to associate more strongly with EBNA-2 binding sites near the LMP-1 and CXCR7 genes. Unbiased motif searching of the EBNA-2 binding regions of the differentially regulated cell genes identified an ETS-interferon regulatory factor composite element motif that closely corresponds to the sequences known to mediate EBNA-2 regulation of the LMP-1 promoter. It appears that the superior induction by type 1 EBNA-2 of the cell genes contributing to cell growth is due to their being regulated in a manner different from that for most EBNA-2-responsive genes and in a way similar to that for the LMP-1 gene. IMPORTANCE: The EBNA-2 transcription factor plays a key role in B cell transformation by EBV and defines the two EBV types. Here we identify a single amino acid (Ser in type 1 EBV, Asp in type 2 EBV) of EBNA-2 that determines the superior ability of type 1 EBNA-2 to induce a key group of cell genes and the EBV LMP-1 gene, which mediate the growth advantage of B cells infected with type 1 EBV. The EBNA-2 binding sites in these cell genes have a sequence motif similar to the sequence known to mediate regulation of the EBV LMP-1 promoter. Further detailed analysis of transactivation and promoter binding provides new insight into the physiological regulation of cell genes by EBNA-2.

Indexed as

Amino AcidsAspartic AcidBinding SitesB-LymphocytesCell LineChromatin ImmunoprecipitationDNA-Binding ProteinsEpstein-Barr Virus Nuclear AntigensGenes, ViralHEK293 CellsHumansPromoter Regions, GeneticReceptors, CXCRSerineTranscriptional ActivationViral Matrix ProteinsACKR3 protein, humanAmino AcidsAspartic AcidDNA-Binding ProteinsEBNA-2 protein, Human herpesvirus 4EBV-associated membrane antigen, Epstein-Barr virusEpstein-Barr Virus Nuclear AntigensReceptors, CXCRSerineViral Matrix ProteinsViral Proteins

Identifiers

PMID24850736
PMCPMC4136291
OpenAlexW1973421649

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.